Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

H.C. Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail

Published 2021-12-29, 11:14 a/m
Updated 2021-12-29, 11:14 a/m
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Aridis Pharmaceuticals Inc 's (NASDAQ:ARDS) monoclonal antibody cocktail treatment is potentially first-in-class, H.C. Wainwright analyst Vernon Bernardino told investors Wednesday.

Last week Aridis announced that the drug, AR-701, is broadly reactive against Omicron and other Covid-19 variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and the common cold, which is a type of human coronavirus.  

According to TheFly, Bernardino, who reiterated a buy rating and $19 price target on Aridis shares, said the cocktail "binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."

The analyst is now looking for the initiation of phase 1 testing as a positive for Aridis Pharmaceuticals' share price next year. 

H.C. Wainwright's positive comments on Aridis follow similar comments from Cantor Fitzgerald, which last week said Aridis' pipeline is "underappreciated."

Despite the bullish commentary on the stock, it is down over 6.8% Wednesday, to $2.04.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.